Single nucleotide polymorphisms (SNPs) in FCγ-receptor genes FCGR3A (rs396991) and FCGR2A (rs1801274) influence the affinity of the Fc portion of anti-CD20 immunoglobulin G1 monoclonal antibody. Their roles in diffuse large B-cell lymphoma (DLBCL) treated with rituximab in combination with anthracycline-based chemotherapy remain controversial. To address this question, we genotyped FCGR2A and FCGR3A SNPs in two prospective DLBCL cohorts from Lymphoma Study Association trials (N = 554) and Iowa/Mayo Specialized Program Of Research Excellence (N = 580). Correlations with treatment response and hematological toxicity were assessed in Lymphoma Study Association. Correlation with event-free survival (EFS) and overall survival (OS) was performed in both cohorts, followed by a meta-analysis to increase power. Our study shows the absence of correlation between these SNPs and treatment response. Grades 3 and 4 febrile neutropenia during treatment was more frequently observed in FCGR3AVV (39%) than VF (29%) and FF (32%) carriers (p = 0.04). Our analysis for EFS and OS shows that FCGR3Awas not associated with outcome. In a metaanalysis using an ordinal model, FCGR2A (per R allele) was associated with a better EFS (hazard ratio = 0.87; 95%CI, 0.76-0.99; p = 0.04) and OS (hazard ratio = 0.86; 95%CI, 0.73-1.00; p = 0.05) which was not altered after adjustment for the International Prognostic Index. Overall, our data demonstrate that patients with DLBCL with the low-affinity FCγRIIA RR had an unexpectedly better outcome than FCγRIIA H carriers. Whether rituximab efficacy is improved in FCγRIIA RR patients due a clearance reduction or other functions of FCγRIIA in DLBCL should be investigated (clinicaltrials.gov identifiers:
Introduction
Rituximab in combination with anthracycline-based chemotherapy has improved the prognosis of patients with diffuse large B-cell lymphoma (DLBCL). Better understanding of factors that affect the response variability of rituximab remains an important therapeutic challenge [1] . Tumour burden had a prognostic impact for patients with DLBCL treated with rituximab in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) regimen, and gender and weight were shown to influence outcome by affecting rituximab clearance [2, 3] .
Antibody-dependent cellular cytotoxicity (ADCC) is one of the major hypothesized mechanisms of action of rituximab [1] . The affinity between Fc portion of anti-CD20 monoclonal antibody and FcG receptors (FCγR) that engages ADCC can be modulated by the presence of single nucleotide polymorphisms (SNPs) in FCGR genes. The FCGR3A rs396991 SNP leading to the substitution of a valine (V) for a phenylalanine (F) confers a higher affinity to FCγRIIIA 158 V for IgG1 than FCγRIIIA 158 F [4] . The FCGR2A rs1801274 SNP modifies an amino-acid at position 131 of FCγRIIA with either a histidine (H) or an arginine (R); FCγRIIA 131H has a higher affinity than FCγRIIA 131R [4] . With rituximab in monotherapy for patients with follicular lymphoma (FL), initial studies showed that FCGR3A VV patients had a better response rate than FCGR3A F carriers [5, 6] . For patients with DLBCL treated with immunochemotherapy, the data on the therapeutic impact of FCGR3A and FCGR2A are unclear based on a relatively small number (51 to 263) of patients with DLBCL [7] [8] [9] [10] [11] [12] . A trend for a higher event-free survival (EFS) was observed for FCGR3A VV compared with FCGR3A F patients treated by R-CHOP in the RICOVER-60 trial [13] . One important observation by the authors of the latter study was that all previous studies were underpowered to observe a statistically significant difference in outcome for FCGR3A or FCGR2A genotype [13] .
We analysed the prognostic value of FCGR2A and FCGR3A in two prospective cohorts (N = 554 and 580) of newly diagnosed patients with DLBCL treated with anthracycline-based chemotherapy and rituximab. We performed a meta-analysis based on these 1134 patients to increase statistical power to clarify this important therapeutic question. We performed exploratory analyses to assess heterogeneity by sex, tumour bulk, and the absolute lymphocyte count (ALC) at diagnosis, which are clinical characteristics known to affect rituximab clearance or efficacy [2, 3, 14] .
Methods

Study population
LYSA cohort
The LNH03B programme of the LYSA consisted of five prospective multicentric, controlled studies including 1704 patients with DLBCL older than 18 years of age [15] [16] [17] [18] [19] . Details of the treatment of 554 patients included in this study are presented in Table S1 in the Supporting Information.
Specialized Program Of Research Excellence cohort
Patients with newly diagnosed lymphoma were enrolled from 2002 to 2009 in the Molecular Epidemiology Resource, a prospective cohort that is part of the University of Iowa/Mayo Clinic Lymphoma Specialized Program of Research Excellence (SPORE) [20] . Details of the treatment, which was based on routine practice, are provided in Table S1 .
This study was conducted in accordance with the Declaration of Helsinki. Ethics committees of Haute-Normandie (LYSA) and the SPORE study Human Subjects Institutional Review Board at Mayo Clinic and the University of Iowa approved this study. All patients provided written consent for participation. In accordance with French law, no mention of race or ethnicity was made.
SNP genotyping
DNA was extracted from peripheral blood. In the LYSA, FCGR3A (rs396991) and FCGR2A (rs1801274) genotyping used a complete assay containing primers, probes, and TaqMan® Genotyping Master Mix from Applied Biosystems (Foster City, California, USA) on an ABI Prism 7000 Sequence Detection System (Applied Biosystems). Duplicate genotyping were performed for 10% of samples, and agreement was 100%. In the SPORE, the FCGR2A SNP was genotyped as part of a larger project using a custom Illumina Infinium array (Illumina, San Diego, CA) and the FCGR3A SNP was genotyped using a custom designed pyrosequencing assay [21] .
Statistical analysis
The correlation between FCGR genotypes and initial characteristics was assessed. Correlation between FCGR3A and FCGR2A genotype and response to treatment and toxicity (grades 3 and 4 anaemia, grades 3 and 4 thrombocytopenia, and grades 3 and 4 febrile neutropenia during treatment, at least one cycle delayed for 5 days or more) were only performed in the LYSA cohort in whom these data were prospectively collected in clinical trial setting. Tumour responses were classified based on the 1999 Cheson criteria [22] . EFS was evaluated from the date of randomization (LYSA) or the date of diagnosis (SPORE) to the date of disease progression, relapse, re-treatment, or death from any cause. Overall survival was evaluated from the date of randomization (LYSA) or the date of diagnosis (SPORE) to the date of death from any cause. A chi-squared test was used to examine associations between genotypes and patient characteristics and treatment response. Survival was estimated by the Kaplan-Meier product limit method and compared using the log-rank test. The prognostic value of each SNP was evaluated for EFS and overall survival (OS) in ordinal (per FCGR3A V and FCGR2A R allele) and genotypic (dominant and recessive) models, first in each cohort, and then in a meta-analysis [23] .
Results
The clinical characteristics of the 554 LYSA and 580 SPORE patients with DLBCL are presented in Table S2 . In the LYSA, the median age was 61 years (range 18-93), 19% had a ECOG PS 0-1, 73% had an Ann Arbor stages III and IV, and 50% had an aaIPI score of 2-3. In the SPORE, the median age was 62 years (range 18-92), 17% had an ECOG PS 0-1. Compared with the LYSA cohort, fewer SPORE patients had Ann Arbor stages III and IV (59% vs 73%), and aaIPI scores 2-3 (41% vs 50%). With a median follow-up of 39 months, the 3-year EFS and OS rates were 69.3% and 75.3%, respectively, in the LYSA cohort. In the SPORE cohort, with a median follow-up of 59 months, the 3-year EFS and OS rates were 66.5% and 79.8% respectively.
Genotyping data were available on 554 LYSA and 580 SPORE patients for FCGR2A and 552 patients for FCGR3A (Table S2 ). The distribution of the VV, VF, and FF alleles for FCGR3A was 15%, 46%, and 39%, respectively, in the LYSA and 11%, 46% and 43%, respectively, in the SPORE. The HH, HR, and RR allele distribution for FCGR2A was 28%, 49%, and 23%, respectively, in the LYSA and 23%, 54%, and 23% in the SPORE. These distributions were consistent with Hardy-Weinberg equilibrium. There was no difference in patient characteristics according to FCGR3A and FCGR2A genotypes in the LYSA (Table S3 ) or in the SPORE (Table S4 ).
FCGR3A and FCGR2A and response to treatment in LYSA patients
For the FCGR3A SNP, complete response (CR) and unconfirmed CR (CRu) after induction therapy were observed in 50 patients (63%) with the VV allele, in 168 patients (68%) with the VF allele, and in 128 patients (63%) with the FF allele (p = 0.44); for FCGR2A SNP, CR/CRu was observed in 93 patients (62%) with the HH Figure 1 . Event-free survival according to FCGR3A and FCGR2A alleles in LYSA and the SPORE cohorts. FCGR3A in LYSA (A) and in the SPORE (B), FCGR2A in LYSA (C) and in the SPORE (D) allele, in 171 patients (66%) with the HR allele, and 82 patients (67%) with the RR allele (p = 0.63). At the end of initial treatment a CR/CRu was documented for 60 (73%), 195 (76%), 158 (74%) patients with respectively FCGR3A VV, VF, and FF genotypes (p = 0.85) and 113 (73%), 202 (75%), 98 (76%) FCGR2A HH, HR, and RR carriers respectively (p = 0.88). Results were similar when analyses were restricted to the 340 and 191 patients assessable for response treated by R-CHOP and R-ACVBP in induction therapy respectively (data not shown).
EFS and OS according to FCGR3A and FCGR2A genotypes (Table 1) . We also did not observe any difference of outcome between patients who carried the high-affinity FCγRIIIA VV genotype compared with patients with the low-affinity FCγRIIIA F allele (genotypic model) (Table S5 ). For FCGR2A, the combined analysis showed that this SNP (per allele) was associated with EFS using an ordinal model (HR = 0.87; 95%CI, 0.79-0.99; p = 0.04) and OS (HR = 0.86; 95%CI, 0.73-1.00; p = 0.05) ( Table 2) . These results retained significance after aaIPI adjustment for EFS (HR = 0.85; 95%CI, 0.74-0.97; p = 0.02) and for OS (HR = 0.83; 95%CI, 0.71-0.97; p = 0.02). While we did not observe any difference of outcome between the high-affinity genotype (FCγRIIA HH) and the low-affinity allele (FCγRIIA R) (genotypic model) (Table S6) Association of FCGR3A and FCGR2A with clinical characteristics
Sex
In LYSA, male patients with the FCGR3A VV genotype compared with FCGR3A F carriers had a poorer OS (HR = 1.86; 95%CI, 1.09-3.19; p = 0.02), but this result was not significant after aaIPI adjustment and was not confirmed in the SPORE (Table S5 ). In the meta-analysis, the beneficial effect on EFS of FCGR2A RR compared with FCGR2A H showed the same trend among men (HR = 0.71; 95%CI, 0.51-0.99; p = 0.05) and women (HR = 0.75; 95%CI, 0.52-1.10; p = 0.14). These results were also observed for OS among men (HR = 0.63; 95%CI, 0.42-0.95; p = 0.03) and women (HR = 0.75; 95%CI, 0.48-1.17; p = 0.20) (Table 3 ).
ALC
We hypothesized that FCGR polymorphisms could display a distinct role in patients with low or high lymphocyte counts. Among patients with a low ALC (<1.0 × 10 9 /L), there was no association of the FCGR3A SNP with either EFS or OS (Tables 1 and S5 EFS: event-free survival; OS: overall survival; HR: hazard ratio; CI: confidence interval; R-CHOP: rituximab, cyclophosphamide, vincristine, and prednisone; ALC: absolute lymphocyte count.
Low and high absolute lymphocyte counts (ALCs) are defined by ALC
Bulky disease
We assessed whether the FCGR3A and FCGR2A SNPs influenced the prognosis of patients with or without a bulky disease, as defined by the presence of a mass >10 cm. We did not observe any association for the FCGR3A (Tables 1  and S5 ) or the FCGR2A (Tables 2 and 3 ) SNPs when stratified on bulky disease.
R-CHOP patients
In LYSA and SPORE, 351 and 511 patients were treated by R-CHOP regimen respectively. There was no association of the FCGR3A with either EFS or OS (Tables 1 and S5 ). 
Hematological toxicities during treatment
Previous reports showed that the degree of neutropenia could be influenced by the FCGR3A SNP for patients treated with rituximab monotherapy after autologous stem cell transplantation [24] or in combination with chemotherapy [8, 25] . We observed that LYSA patients with FCGR3A VV genotype (N = 32, 39%) were more likely to have at least one febrile neutropenia (grades 3 and 4) during treatment than FCGR3A VF (N = 75, 29%) and FCGR3A FF (N = 69, 32%) genotypes (p = 0.04). The FCGR2A SNP was not associated with the rate of febrile neutropenia. Neither SNP was associated with anemia, thrombocytopenia, or the number of cycles applied with a delay of ≥5 days.
Discussion
Eight smaller series (51 to 263 patients with DLBCL), likely underpowered [13] , reported weak and not statistically significant correlations between these two FCGR SNPs and prognosis after immunochemotherapy [7] [8] [9] [10] [11] [12] . We performed a meta-analysis of two large and independent cohorts to overcome this limitation. We found no association for the FCGR3A SNP with EFS or OS in patients with DLBCL treated by rituximab and anthracycline-based chemotherapy, confirming five EFS: event-free survival; OS: overall survival; HR: hazard ratio; CI: confidence interval; R-CHOP: rituximab, cyclophosphamide, vincristine, and prednisone; ALC: absolute lymphocyte count.
Low and high absolute lymphocyte counts (ALCs) are defined by ALC previous smaller studies [7, 8, [10] [11] [12] . The prognostic effect of the FCGR3A SNP has mainly been observed in patients with FL treated by single-agent rituximab in retrospective studies [5, 6, 14] , although these results were not confirmed prospectively [26] . One explanation for the lack of prognostic value of FCGR3A SNP in the context of immunochemotherapy is that the association between chemotherapy and rituximab is deleterious for ADCC effectors. Another hypothesis is that the rituximab dose (375 mg/m 2 ) used in the immunochemotherapy schedule abrogated the rituximab activity modulation of FCGR3A SNP, which was only observed at low concentration (<0.01 μg/mL) in an in vitro study [27] . Our data are consistent with results from FL and chronic lymphocytic leukaemia in which FCGR3A had no prognostic impact when patients were treated by immunochemotherapy [28, 29] . With respect to hematological toxicity, FCGR3A VV patients had more frequent grades 3 and 4 neutropenia during immunochemotherapy, which is consistent with previous reports [8, 25] .
Our results for the FCGR2A SNP were unexpected, given that we observed that the low-affinity FCγRIIA 131RR genotype had a modest but significantly better outcome than the high-affinity FCγRIIA 131H carriers. In DLBCL, most studies have not observed any prognostic effect of the FCGR2A SNP for patients treated with immunochemotherapy [7, 9, 10, 12, 13 ]. An increase susceptibility to systemic lupus erythematous had been described for FCGR2A RR carriers in relation with a reduced ability of FCγRII 131RR to clear immune complexes leading to their increased depositions in tissues [30] . With anti-tumour necrosis factor-α monoclonal antibodies, patients with rheumatoid arthritis who carry FCγRII 131RR genotype had a better clinical response with a reduced clearance of infliximab in the circulation [31] . One hypothesis could be that FCγRII 131RR carriers have a reduced clearance of rituximab that increases anti-CD20 availability. Unfortunately, no rituximab dosage was available in our series to explore this hypothesis. In the study of Muller et al. assessing the rituximab clearance in DLBCL, they observed that after completion of immunochemotherapy, rituximab remained detectable in patient sera up to 9 months (median 1.1 μg/mL, range 0-2.8) [3] . Whether FCGR2A SNP is able to modulate residual rituximab clearance after initial treatment should be investigated with the hypothesis being that FCGR2A RR compared with FCGR2A H patients retain higher rituximab serum levels that could be active on residual disease. We also observed this trend for FCGR2A SNP in patients with FL included in Primary Rituximab and Maintenance study [29] . After induction immunochemotherapy, among patients with FL randomized in the observational arm, FCGR2A RR patients had a non-significant but clear trend for a better 3-year PFS (62.5%) compared with FCGR2A HR (52.7%) and FCGR2A HH (54.4%) carriers Table 3 . Association of low-affinity FCγRIIA RR versus high-affinity FCγRIIA H with event-free and overall survival EFS: event-free survival; OS: overall survival; HR: hazard ratio; CI: confidence interval; R-CHOP: rituximab, cyclophosphamide, vincristine and prednisone; ALC: absolute lymphocyte count.
Low and high absolute lymphocyte counts (ALCs) are defined by ALC (p = 0.26), but in the rituximab maintenance arm, the PFS curves of the three FCGR2A genotypes were all superimposed. One hypothesis is that the addition of rituximab every 2 months for 2 years abolished the effect of FCγRIIA 131RR observed after initial treatment in the observational arm.
FCγRIIA is the receptor of the C-reactive protein (CRP), and FCγRIIA 131RR has a better affinity with CRP than FCγRIIA 131H [32] . In pneumococcal diseases, patients with FCγRIIA 131RR have a higher affinity for CRP and an increase of proinflammatory cytokine response [33] . A study found a protective effect of FCγRIIA 131RR for patients with invasive pneumococcal diseases with lower hospital mortality [34] . It would be interesting to investigate whether FCγRIIA modulates inflammatory response in DLBCL. A role in lymphoma pathogenesis cannot be excluded, as the FCGR2A SNP has been implicated in lymphoma susceptibility [35] .
While sex and tumour burden could affect rituximab clearance and efficacy in DLBCL [2, 3] , we did not observe any significant associations in analyses stratified by sex or by tumour burden, although power was lower for these analyses. We observed that the better prognosis of FCGR2A RR seemed more pronounced in high compared with low ALC patients. It would be interesting to have a larger patient sample size to investigate if FCGR2A RR patients with higher immune effectors have a better benefit of rituximab treatment compared with FCGR2A H patients.
One limitation of our study is that patients were not treated homogeneously. In the LYSA trials two types of induction treatment (R-CHOP and R-ACVBP) and different consolidation therapies were used. Patients in the SPORE lacked a controlled treatment trial setting, but both cohorts were very similar from clinical, genotype frequency and outcomes perspectives. We did not perform any correction test in our statistical analysis: the primary objective of the study was to test previously reported effect of FCGR3A and FCGR2A SNPs in two large prospective DLBCL cohorts and perform a meta-analysis to gain statistical power. Our results for the subgroup analyses should be viewed as exploratory.
In conclusion, in these two large prospective cohorts, we observed no association of the FCGR3A rs396991 SNP and DLBCL outcome. Somewhat unexpectedly, the FCGR2A rs1801274 SNP influenced DLBCL outcome. While the effect was relatively weak, it suggests a reevaluation of the relation of FCγRIIA and rituximab clearance and its impact on DLBCL pathogenesis.
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